All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

biperiden 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
	374	514-65-8

Description:

Molecule

Description

Molfile Inchi Smiles Synonyms: biperiden akineton biperiden hydrochloride biperiden lactate biperiden HCl

A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine. Molecular weight: 311.47 Formula: C21H29NO CLOGP: 4.94 LIPINSKI: 0 HAC: 2 HDO: 1 TPSA: 23.47 ALOGS: -4.86 ROTB: 5 Status: OFM Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
10	mg	O
10	mg	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	1 mg/mL	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.64 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	30 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	12 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	12 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.10 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	24 hours	Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	2.594		High	1
caco2-efflux	Caco-2 efflux ratio (BA/AB)	0.899		High	1
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	28.576	10^-6 cm/s	High	1
dh-clint	Dog hepatocyte intrinsic clearance	28.576	uL/min/10^6 cells	High	1
dppb	Dog plasma protein binding (% unbound)	12.400	%	High	1
fcs-ppb	Fetal calf serum protein binding (% unbound)	23.610	%	High	1
herg	hERG pIC50	5.367	pIC50	High	1
hh-clint	Human hepatocyte intrinsic clearance	6.266	uL/min/10^6 cells	High	1
hlm-clint	Human liver microsomal intrinsic clearance	17.947	uL/min/mg protein	High	1
hppb	Human plasma protein binding (% unbound)	11.250	%	High	1
kinase-safety-class	ACVR2A,ACVR2B,AKT1,AKT2,AKT3,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,JAK3,MAP3K7,MAPK10,MAPK12,MAPK7,MAPKAPK2,MET,NTRK2,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PRKDC,SIK2,SIK3,STK33,TEK,TGFBR1,TTK	42
kinase-selectivity-class	AXL,CAMK2D,CDK4,EIF2AK3,EPHB4,GRK2,PDK4,SIK2,STK33	9
mdck-mdr1-bcrp-efflux	MDCK-MDR1-BCRP efflux ratio	0.564		High	1
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	0.350		High	1
mh-clint	Mouse hepatocyte intrinsic clearance	74.645		High	1
mppb	Mouse plasma protein binding (% unbound)	11.390		High	1
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	1.710		High	1
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pppb	Pig plasma protein binding (% unbound)	22.830	%	High	1
rat-kpuu-brain	Rat brain Kpuu	0.352	%	High	1
rh-clint	Rat hepatocyte intrinsic clearance	249.459	uL/min/10^6 cells	High	1
rh-fuinc	Rat hepatocyte fraction unbound in incubation	37.330	%	High	1
rppb	Rat plasma protein binding (% unbound)	14.600	%	High	1
solubility-dd	Solubility at pH 7.4 in DMSO	544.503	uM	High	1

Approvals:

Date	Agency	Company	Orphan
Sept. 8, 1959	FDA	ABBVIE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Neuroleptic malignant syndrome	412.81	30.79	115	7026	14981	90606325
Suicide attempt	211.90	30.79	108	7033	75291	90546015
Extrapyramidal disorder	203.49	30.79	68	7073	16235	90605071
Drug interaction	198.49	30.79	168	6973	276285	90345021
Intentional overdose	176.35	30.79	103	7038	93731	90527575
Intentional self-injury	144.50	30.79	62	7079	29272	90592034
Hyperprolactinaemia	142.03	30.79	40	7101	5393	90615913
Akathisia	141.03	30.79	47	7094	11112	90610194
Psychotic symptom	129.25	30.79	31	7110	2225	90619081
Sopor	121.07	30.79	52	7089	24592	90596714
Drug abuse	120.32	30.79	77	7064	82270	90539036
Dyskinesia	119.27	30.79	58	7083	36476	90584830
Salivary hypersecretion	117.71	30.79	39	7102	9053	90612253
Schizophrenia	116.71	30.79	44	7097	14870	90606436
Restlessness	114.48	30.79	56	7085	35664	90585642
Somnolence	110.25	30.79	107	7034	208977	90412329
Delusion	98.12	30.79	38	7103	13802	90607504
Muscle rigidity	96.89	30.79	38	7103	14271	90607035
Altered state of consciousness	93.81	30.79	47	7094	31485	90589821
Toxicity to various agents	93.34	30.79	114	7027	287732	90333574
Hallucination, auditory	92.84	30.79	38	7103	15937	90605369
Tremor	91.41	30.79	84	7057	153089	90468217
Oromandibular dystonia	83.03	30.79	17	7124	586	90620720
Dystonia	77.72	30.79	34	7107	16785	90604521
Blood creatine phosphokinase increased	76.35	30.79	42	7099	33981	90587325
Coma	73.09	30.79	54	7087	72578	90548728
Logorrhoea	70.91	30.79	20	7121	2707	90618599
Agitation	67.77	30.79	50	7091	67048	90554258
Persecutory delusion	67.70	30.79	20	7121	3188	90618118
Dysarthria	65.15	30.79	45	7096	54437	90566869
Inappropriate affect	63.46	30.79	15	7126	1010	90620296
Rhabdomyolysis	62.85	30.79	43	7098	51213	90570093
Confabulation	62.02	30.79	12	7129	308	90620998
Parkinsonism	60.37	30.79	27	7114	14038	90607268
Galactorrhoea	60.30	30.79	20	7121	4652	90616654
Psychomotor hyperactivity	59.52	30.79	26	7115	12787	90608519
Mental impairment	55.91	30.79	27	7114	16693	90604613
Sluggishness	55.53	30.79	20	7121	5939	90615367
Resting tremor	55.08	30.79	13	7128	870	90620436
Reduced facial expression	54.24	30.79	16	7125	2537	90618769
Bradykinesia	52.99	30.79	20	7121	6768	90614538
Negative symptoms in schizophrenia	51.95	30.79	9	7132	122	90621184
Blood prolactin increased	48.66	30.79	16	7125	3621	90617685
Cogwheel rigidity	48.30	30.79	14	7127	2088	90619218
Urinary incontinence	47.20	30.79	32	7109	37534	90583772
Pneumonia aspiration	44.71	30.79	32	7109	40908	90580398
Treatment noncompliance	44.40	30.79	35	7106	51692	90569614
Psychomotor retardation	44.35	30.79	16	7125	4773	90616533
Catatonia	44.24	30.79	17	7124	6039	90615267
Ileus paralytic	43.41	30.79	16	7125	5069	90616237
Rabbit syndrome	43.39	30.79	9	7132	331	90620975
Megacolon	43.23	30.79	13	7128	2201	90619105
Hypothermia	42.76	30.79	22	7119	15553	90605753
Arthralgia	41.61	30.79	6	7135	778516	89842790
Hyperammonaemic encephalopathy	40.69	30.79	13	7128	2686	90618620
Urinary retention	40.07	30.79	29	7112	37715	90583591
Depressed level of consciousness	39.67	30.79	38	7103	72746	90548560
Stupor	38.66	30.79	15	7126	5467	90615839
Parkinsonian gait	38.41	30.79	9	7132	583	90620723
Electrocardiogram QT prolonged	37.93	30.79	37	7104	72419	90548887
Serotonin syndrome	37.71	30.79	28	7113	37859	90583447
Tardive dyskinesia	37.60	30.79	18	7123	10912	90610394
Eosinophilic myocarditis	37.11	30.79	9	7132	676	90620630
Accommodation disorder	36.06	30.79	8	7133	406	90620900
Psychotic disorder	35.46	30.79	25	7116	31205	90590101
Stereotypy	35.29	30.79	8	7133	448	90620858
Parkinsonism hyperpyrexia syndrome	34.36	30.79	7	7134	235	90621071
Distractibility	33.66	30.79	8	7133	551	90620755
Oculogyric crisis	33.54	30.79	11	7130	2468	90618838
Mutism	32.88	30.79	10	7131	1759	90619547
Hypertonia	32.47	30.79	13	7128	5142	90616164
Headache	32.06	30.79	14	7127	862732	89758574
Psychiatric decompensation	31.95	30.79	10	7131	1933	90619373
Drug monitoring procedure incorrectly performed	31.93	30.79	7	7134	336	90620970
Delirium	31.57	30.79	40	7101	104319	90516987
Sitting disability	31.48	30.79	7	7134	359	90620947
Cerebral atrophy	31.33	30.79	13	7128	5633	90615673
Hallucinations, mixed	30.80	30.79	13	7128	5876	90615430

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Neuroleptic malignant syndrome	270.46	25.94	113	7743	21359	42592120
Schizophrenia	165.31	25.94	65	7791	10485	42602994
Colitis ischaemic	158.65	25.94	57	7799	7169	42606310
Extrapyramidal disorder	131.54	25.94	63	7793	16349	42597130
Salivary hypersecretion	119.16	25.94	52	7804	10891	42602588
Intentional self-injury	114.70	25.94	56	7800	15146	42598333
Sopor	112.89	25.94	53	7803	13149	42600330
Megacolon	102.74	25.94	31	7825	2254	42611225
Suicide attempt	101.51	25.94	77	7779	46023	42567456
Delusion	98.51	25.94	50	7806	14684	42598795
Muscle rigidity	89.69	25.94	44	7812	12015	42601464
Psychotic disorder	87.82	25.94	59	7797	29149	42584330
Ileus paralytic	82.16	25.94	36	7820	7605	42605874
Altered state of consciousness	78.27	25.94	55	7801	29204	42584275
Self-injurious ideation	78.24	25.94	24	7832	1844	42611635
Hallucination, auditory	78.24	25.94	43	7813	14821	42598658
Aggression	76.31	25.94	64	7792	44099	42569380
Dyskinesia	75.63	25.94	51	7805	25339	42588140
Intentional overdose	73.68	25.94	67	7789	51389	42562090
Depressed level of consciousness	71.72	25.94	64	7792	47906	42565573
Akathisia	71.41	25.94	36	7820	10415	42603064
Restlessness	69.12	25.94	51	7805	29198	42584281
Blood creatine phosphokinase increased	67.37	25.94	62	7794	48276	42565203
Sedation	67.25	25.94	51	7805	30424	42583055
Psychomotor hyperactivity	66.92	25.94	35	7821	10923	42602556
Persecutory delusion	66.67	25.94	25	7831	3539	42609940
Pneumonia aspiration	65.50	25.94	62	7794	50016	42563463
Parkinsonism	65.07	25.94	34	7822	10589	42602890
Oropharyngeal spasm	62.06	25.94	13	7843	207	42613272
Psychiatric symptom	59	25.94	24	7832	4217	42609262
Stupor	58.55	25.94	22	7834	3131	42610348
Faecaloma	56.14	25.94	26	7830	6244	42607235
Delirium	50.36	25.94	55	7801	52464	42561015
Patient restraint	47.99	25.94	9	7847	78	42613401
Drug interaction	47.89	25.94	132	7724	266867	42346612
Tremor	47.81	25.94	73	7783	96856	42516623
Peritonitis	47.44	25.94	34	7822	18599	42594880
Dysphagia	46.51	25.94	62	7794	72657	42540822
Psychomotor retardation	44.94	25.94	20	7836	4379	42609100
Sinus tachycardia	44.31	25.94	34	7822	20619	42592860
Postoperative respiratory failure	43.85	25.94	9	7847	129	42613350
Dystonia	43.69	25.94	28	7828	12762	42600717
Rhabdomyolysis	43.12	25.94	62	7794	77957	42535522
Post-injection delirium sedation syndrome	39.57	25.94	11	7845	597	42612882
Self-destructive behaviour	39.56	25.94	10	7846	375	42613104
Tardive dyskinesia	36.34	25.94	20	7836	6904	42606575
Polydipsia	35.23	25.94	17	7839	4471	42609008
Psychotic symptom	34.88	25.94	14	7842	2376	42611103
Paraplegia	33.71	25.94	15	7841	3282	42610197
Hyponatraemia	32.34	25.94	63	7793	101399	42512080
Overdose	31.91	25.94	64	7792	105200	42508279
Treatment noncompliance	31.91	25.94	37	7819	37635	42575844
Bezoar	31.54	25.94	11	7845	1265	42612214
Disorientation	31.25	25.94	36	7820	36353	42577126
Tension	31.07	25.94	13	7843	2451	42611028
Olfactory nerve disorder	30.87	25.94	6	7850	64	42613415
Shock	28.77	25.94	31	7825	29090	42584389
Coma	28.76	25.94	42	7814	53512	42559967
Arthralgia	27.30	25.94	3	7853	205235	42408244
Social avoidant behaviour	27.19	25.94	13	7843	3351	42610128
Drug screen false positive	27.09	25.94	9	7847	893	42612586
Pseudohallucination	27.02	25.94	5	7851	40	42613439
Agitation	26.95	25.94	45	7811	64269	42549210
Sudden death	26.45	25.94	23	7833	16606	42596873
Paraparesis	26.36	25.94	11	7845	2060	42611419
Fatigue	26.32	25.94	25	7831	435616	42177863

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Neuroleptic malignant syndrome	653.81	25.53	223	14370	33836	110540870
Extrapyramidal disorder	319.18	25.53	126	14467	28741	110545965
Suicide attempt	255.73	25.53	163	14430	103231	110471475
Schizophrenia	250.85	25.53	98	14495	21728	110552978
Salivary hypersecretion	231.66	25.53	87	14506	17334	110557372
Intentional self-injury	224.32	25.53	106	14487	37323	110537383
Sopor	220.56	25.53	104	14489	36442	110538264
Delusion	215.55	25.53	90	14503	23665	110551041
Akathisia	200.74	25.53	78	14515	17035	110557671
Drug interaction	199.56	25.53	285	14308	499898	110074808
Muscle rigidity	181.61	25.53	80	14513	23951	110550755
Dyskinesia	173.39	25.53	99	14494	51347	110523359
Hallucination, auditory	171.28	25.53	79	14514	26318	110548388
Altered state of consciousness	168.13	25.53	101	14492	57525	110517181
Colitis ischaemic	163.54	25.53	68	14525	17682	110557024
Intentional overdose	160.95	25.53	136	14457	132365	110442341
Psychotic symptom	152.68	25.53	44	14549	3823	110570883
Restlessness	149.77	25.53	93	14500	56166	110518540
Blood creatine phosphokinase increased	148.53	25.53	102	14491	72975	110501731
Megacolon	139.36	25.53	42	14551	4263	110570443
Persecutory delusion	135.57	25.53	45	14548	6246	110568460
Hyperprolactinaemia	133.63	25.53	45	14548	6530	110568176
Tremor	132.73	25.53	148	14445	202084	110372622
Ileus paralytic	132.35	25.53	52	14541	11685	110563021
Parkinsonism	124.25	25.53	60	14533	22127	110552579
Psychomotor hyperactivity	123.20	25.53	58	14535	20219	110554487
Pneumonia aspiration	118.88	25.53	93	14500	81140	110493566
Aggression	118.78	25.53	82	14511	59128	110515578
Psychotic disorder	115.22	25.53	76	14517	50861	110523845
Dystonia	109.95	25.53	58	14535	25747	110548959
Rhabdomyolysis	107.55	25.53	104	14489	120297	110454409
Depressed level of consciousness	106.01	25.53	100	14493	112178	110462528
Agitation	99.75	25.53	97	14496	112954	110461752
Stupor	94.53	25.53	37	14556	8228	110566478
Somnolence	93.48	25.53	152	14441	297297	110277409
Oromandibular dystonia	91.32	25.53	23	14570	1196	110573510
Psychomotor retardation	89.53	25.53	35	14558	7757	110566949
Self-injurious ideation	89.32	25.53	30	14563	4316	110570390
Coma	87.28	25.53	92	14501	117777	110456929
Psychiatric symptom	80.51	25.53	34	14559	9179	110565527
Delirium	80.35	25.53	94	14499	134931	110439775
Sedation	79.38	25.53	69	14524	69614	110505092
Drug abuse	79.25	25.53	107	14486	177304	110397402
Treatment noncompliance	76.62	25.53	69	14524	72921	110501785
Faecaloma	76.53	25.53	38	14555	14870	110559836
Arthralgia	72.25	25.53	9	14584	779623	109795083
Toxicity to various agents	69.58	25.53	178	14415	480377	110094329
Tardive dyskinesia	67.89	25.53	34	14559	13545	110561161
Dysarthria	64.66	25.53	67	14526	84054	110490652
Nausea	63.24	25.53	43	14550	1235647	109339059
Bradykinesia	62.89	25.53	30	14563	10758	110563948
Dysphagia	61.63	25.53	88	14505	153512	110421194
Headache	58.08	25.53	22	14571	882355	109692351
Electrocardiogram QT prolonged	56.87	25.53	71	14522	108889	110465817
Inappropriate affect	56.82	25.53	17	14576	1682	110573024
Logorrhoea	56.01	25.53	22	14571	4935	110569771
Overdose	55.88	25.53	106	14487	233688	110341018
Oropharyngeal spasm	55.76	25.53	13	14580	487	110574219
Catatonia	55.63	25.53	28	14565	11272	110563434
Disorientation	55.59	25.53	57	14536	70614	110504092
Urinary retention	54.44	25.53	56	14537	69627	110505079
Pain	53.28	25.53	30	14563	954925	109619781
Fatigue	52.58	25.53	50	14543	1215908	109358798
Hypothermia	51.72	25.53	36	14557	26266	110548440
Intentional product misuse	51.64	25.53	75	14518	132829	110441877
Reduced facial expression	51.31	25.53	19	14574	3632	110571074
Cogwheel rigidity	51.08	25.53	19	14574	3679	110571027
Mutism	50.46	25.53	18	14575	3095	110571611
Confabulation	50.02	25.53	12	14581	509	110574197
Irritability	49.77	25.53	45	14548	47764	110526942
Patient restraint	49.39	25.53	9	14584	95	110574611
Social avoidant behaviour	47.53	25.53	20	14573	5349	110569357
Peritonitis	46.95	25.53	37	14556	32570	110542136
Mental impairment	46.90	25.53	32	14561	22607	110552099
Blood prolactin increased	46.88	25.53	19	14574	4623	110570083
Galactorrhoea	45.40	25.53	18	14575	4137	110570569
Post-injection delirium sedation syndrome	45.38	25.53	12	14581	757	110573949
Hyponatraemia	43.96	25.53	92	14501	217561	110357145
Negative symptoms in schizophrenia	42.66	25.53	9	14584	211	110574495
Torticollis	42.48	25.53	16	14577	3205	110571501
Postoperative respiratory failure	42.46	25.53	9	14584	216	110574490
Refusal of treatment by patient	42.31	25.53	22	14571	9472	110565234
Disorganised speech	42.09	25.53	16	14577	3287	110571419
Intestinal pseudo-obstruction	41.85	25.53	16	14577	3340	110571366
Shock	41.74	25.53	43	14550	53545	110521161
Sluggishness	40.96	25.53	20	14573	7547	110567159
Sinus tachycardia	40.76	25.53	39	14554	44454	110530252
Resting tremor	39.83	25.53	13	14580	1710	110572996
Inappropriate antidiuretic hormone secretion	39.51	25.53	34	14559	33817	110540889
Sudden death	37.99	25.53	29	14564	24366	110550340
Urinary incontinence	37.86	25.53	39	14554	48548	110526158
Pain in extremity	37.69	25.53	9	14584	487109	110087597
Rabbit syndrome	37.55	25.53	9	14584	380	110574326
Hyperammonaemic encephalopathy	37.55	25.53	17	14576	5417	110569289
Abnormal behaviour	37.24	25.53	35	14558	39004	110535702
Drug level increased	36.64	25.53	38	14555	47681	110527025
Hypersensitivity	36.56	25.53	5	14588	403993	110170713
Oculogyric crisis	36.36	25.53	15	14578	3817	110570889
Disturbance in attention	34.93	25.53	42	14551	61953	110512753
Polydipsia	34.79	25.53	18	14575	7670	110567036
Olfactory nerve disorder	34.77	25.53	6	14587	45	110574661
Hallucination	34.77	25.53	54	14539	101378	110473328
Leukocytosis	34.56	25.53	39	14554	53789	110520917
Spasmodic dysphonia	34.06	25.53	9	14584	566	110574140
Asthenia	33.79	25.53	25	14568	688974	109885732
Intestinal dilatation	33.77	25.53	14	14579	3606	110571100
Cough	32.94	25.53	10	14583	461631	110113075
Accommodation disorder	32.93	25.53	9	14584	644	110574062
Paraplegia	32.40	25.53	16	14577	6184	110568522
Drug hypersensitivity	32.10	25.53	10	14583	454080	110120626
Dyspnoea	32.05	25.53	61	14532	1106811	109467895
Dysphoria	31.85	25.53	16	14577	6412	110568294
Hypernatraemia	31.80	25.53	23	14570	17810	110556896
Rash	31.76	25.53	37	14556	820927	109753779
Pruritus	31.33	25.53	19	14574	581541	109993165
Drug monitoring procedure incorrectly performed	31.31	25.53	9	14584	774	110573932
White blood cell count increased	31.04	25.53	50	14543	96792	110477914
Neutrophil count increased	31.03	25.53	30	14563	34622	110540084
Suicidal ideation	30.79	25.53	49	14544	93888	110480818
Loss of consciousness	30.72	25.53	75	14518	196231	110378475
Hypertonia	30.52	25.53	17	14576	8389	110566317
Akinesia	30.27	25.53	13	14580	3654	110571052
Swelling	30.25	25.53	5	14588	351036	110223670
Distractibility	30.06	25.53	9	14584	892	110573814
Obsessive-compulsive disorder	30.05	25.53	16	14577	7225	110567481
Eosinophilic myocarditis	29.85	25.53	11	14582	2074	110572632
Hallucination, visual	29.44	25.53	31	14562	39574	110535132
Abdominal discomfort	29.07	25.53	8	14585	393850	110180856
Seizure	28.94	25.53	79	14514	221106	110353600
Parkinsonism hyperpyrexia syndrome	28.77	25.53	8	14585	610	110574096
Drug intolerance	28.64	25.53	9	14584	406503	110168203
Parkinsonian gait	28.52	25.53	9	14584	1063	110573643
Gaze palsy	27.87	25.53	12	14581	3395	110571311
Diarrhoea	27.07	25.53	70	14523	1139435	109435271
Drug screen false positive	26.36	25.53	9	14584	1360	110573346
Tension	26.22	25.53	13	14580	5065	110569641
Self-destructive behaviour	26.21	25.53	8	14585	847	110573859
Thinking abnormal	25.80	25.53	19	14574	15121	110559585
Gastrointestinal necrosis	25.68	25.53	14	14579	6626	110568080
Colectomy total	25.66	25.53	7	14586	497	110574209
Negativism	25.55	25.53	8	14585	921	110573785

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N04AA02	NERVOUS SYSTEM ANTI-PARKINSON DRUGS ANTICHOLINERGIC AGENTS Tertiary amines
FDA MoA	N0000175370	Cholinergic Antagonists
FDA EPC	N0000175574	Anticholinergic
CHEBI has role	CHEBI:35469	antidepressant
CHEBI has role	CHEBI:35474	anxiolytic drug
CHEBI has role	CHEBI:35476	antipsychotic agent
CHEBI has role	CHEBI:48407	antiparkinson drug
CHEBI has role	CHEBI:48876	muscarinic antagonist
CHEBI has role	CHEBI:50370	parasympatholytic
CHEBI has role	CHEBI:66956	antidyskinesia agent
CHEBI has role	CHEBI:136860	antidote to sarin poisoning
MeSH PA	D000978	Antiparkinson Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D010276	Parasympatholytics
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018678	Cholinergic Agents
MeSH PA	D018680	Cholinergic Antagonists
MeSH PA	D018726	Anti-Dyskinesia Agents
MeSH PA	D018727	Muscarinic Antagonists
CHEBI has role	CHEBI:63726	neuroprotective agent

Related Drugs by ATC class:

N04AA Tertiary amines 9 drugs

bornaprinedexetimidemazaticolmetixenephenglutarimideprocyclidineprofenaminetrihexyphenidyltropatepine

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Postencephalitic parkinsonism	indication	19972008	DOID:14332
Parkinsonism	indication	32798002
Parkinson's disease	indication	49049000	DOID:14330
Extrapyramidal disease	indication	76349003
Arteriosclerotic Parkinsonism	indication
Urinary tract obstruction	contraindication	7163005	DOID:5200
Chronic obstructive lung disease	contraindication	13645005	DOID:3083
Severe chronic ulcerative colitis	contraindication	14311001
Disorder of autonomic nervous system	contraindication	15241006
Toxic megacolon	contraindication	28536002	DOID:1770
Atony of colon	contraindication	29479008
Shigellosis	contraindication	36188001
Hypertensive disorder	contraindication	38341003	DOID:10763
Conduction disorder of the heart	contraindication	44808001
Low blood pressure	contraindication	45007003
Achalasia of esophagus	contraindication	45564002	DOID:9164
Chronic heart failure	contraindication	48447003
Dysuria	contraindication	49650001
Paralytic ileus	contraindication	55525008	DOID:8442
Ulcerative colitis	contraindication	64766004	DOID:8577
Hiatal hernia	contraindication	84089009	DOID:12642
Open-angle glaucoma	contraindication	84494001	DOID:1067
Kidney disease	contraindication	90708001	DOID:557
Thyrotoxicosis	contraindication	90739004	DOID:7997
Myasthenia gravis	contraindication	91637004	DOID:437
Tardive dyskinesia	contraindication	102449007
Dysentery	contraindication	111939009
Gastrointestinal obstruction	contraindication	126765001
Bleeding	contraindication	131148009
Gastroesophageal reflux disease	contraindication	235595009	DOID:8534
Disease of liver	contraindication	235856003	DOID:409
Benign prostatic hyperplasia	contraindication	266569009
Retention of urine	contraindication	267064002
Fever	contraindication	386661006
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Pseudomembranous enterocolitis	contraindication	397683000
Gastric ulcer	contraindication	397825006	DOID:10808
Disorder of coronary artery	contraindication	414024009

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.2	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN	ANTAGONIST	Kd	9.32		IUPHAR	CHEMBL
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN	ANTAGONIST	Kd	8.20		IUPHAR
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN	ANTAGONIST	Kd	8.41		IUPHAR
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN	ANTAGONIST	Kd	8.62		IUPHAR
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	8.20		PDSP
Neuronal acetylcholine receptor subunit alpha-2	Ion channel	Q15822	ACHA2_HUMAN					WOMBAT-PK

External reference:

ID	Source
4019635	VUID
N0000147728	NUI
D00779	KEGG_DRUG
151311	RXNORM
C0005578	UMLSCUI
CHEBI:3112	CHEBI
CHEMBL1101	ChEMBL_ID
CHEMBL1201035	ChEMBL_ID
CHEMBL1201067	ChEMBL_ID
DB00810	DRUGBANK_ID
D001712	MESH_DESCRIPTOR_UI
2381	PUBCHEM_CID
7128	IUPHAR_LIGAND_ID
915	INN_ID
1235-82-1	SECONDARY_CAS_RN
7085-45-2	SECONDARY_CAS_RN
0FRP6G56LD	UNII
4285	MMSL
d00972	MMSL
10020007	SNOMEDCT_US
387359004	SNOMEDCT_US
61742009	SNOMEDCT_US
65041000	SNOMEDCT_US
4018474	VANDF
4018475	VANDF
4019635	VANDF
C036432	MESH_SUPPLEMENTAL_RECORD_UI
001644	NDDF
001645	NDDF
001646	NDDF
0FRP6G56LD	INXIGHT DRUGS

Pharmaceutical products:

None